Investor
Ally Bridge Group (NY) LLC
CIK 0001822947 · filed 2026-05-18 · SEC filing
13F book
$123.8M
Positions
21
10 new · 2 sold
Largest name
8.5%
Praxis Precision Medicines I
Est. mark
$6.55M
Price effect on 11 names still held. Flow $31.1M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I | — | 32.8K | $10.6M | 8.5% | $545.8K | Added$4.71M |
| Minerva Neurosciences, Inc. | NERV | 1.66M | $9.97M | 8.1% | $3.32M | Held |
| Soleno Therapeutics Inc | — | 200K | $6.7M | 5.4% | −$2.15M | Added−$1.08M |
| Ovid Therapeutics Inc. | OVID | 2.82M | $6.26M | 5.1% | $1.05M | Added$3.35M |
| Compass Pathways Plc | CMPS | 1.04M | $5.78M | 4.7% | — | New |
| Tarsus Pharmaceuticals, Inc. | TARS | 80.9K | $5.67M | 4.6% | — | New |
| Solid Biosciences Inc. | SLDB | 767K | $5.52M | 4.5% | $645.3K | Added$3.19M |
| ProMIS Neurosciences Inc. | PMN | 414.2K | $5.26M | 4.2% | $1.46M | Added$3.56M |
| Edgewise Therapeutics, Inc. | EWTX | 161K | $5.07M | 4.1% | $1.08M | Cut$232.6K |
| Eupraxia Pharmaceuticals Inc. | EPRX | 660.4K | $4.78M | 3.9% | −$123.3K | Added$1.78M |
| CytomX Therapeutics, Inc. | CTMX | 900K | $4.23M | 3.4% | — | New |
| Inventiva Sa | — | 745.3K | $4.14M | 3.3% | $670.8K | Cut−$2.84M |
| Perspective Therapeutics, Inc. | CATX | 926.6K | $3.86M | 3.1% | — | New |
| Abivax Sa | — | 33.7K | $3.75M | 3.0% | −$792.4K | Cut−$5.69M |
| Alumis Inc. | ALMS | 167K | $3.68M | 3.0% | — | New |
| UroGen Pharma Ltd. | URGN | 202.1K | $3.63M | 2.9% | — | New |
| Capricor Therapeutics, Inc. | CAPR | 113.9K | $3.46M | 2.8% | — | New |
| Whitehawk Therapeutics, Inc. | WHWK | 817.9K | $2.82M | 2.3% | $842.5K | Held |
| Inhibikase Therapeutics, Inc. | IKT | 1.32M | $2.23M | 1.8% | — | New |
| AN2 Therapeutics, Inc. | ANTX | 526.3K | $1.8M | 1.5% | — | New |
| Relmada Therapeutics, Inc. | RLMD | 210.5K | $1.47M | 1.2% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.